TYK2 Inhibition: Evolving Options in Psoriasis Care - Episode 11

Therapeutic Potential of TYK2 Inhibition in Psoriatic Arthritis

Published on: January 5, 2026

Christopher G. Bunick, MD, PhD, April W. Armstrong, MD, MPH

Panelists discuss the questions below in this video. What do we know about the therapeutic potential of TYK2 inhibition in psoriatic arthritis?

EP. 1: Cytokine Pathways and Their Impact on Plaque Psoriasis

EP. 2: Current Standard of Care and Treatment Options in Psoriasis

EP. 3: Role of Mechanisms of Action in Treatment Decisions and Personalized Care in Psorias

EP. 4: Challenges with Current Psoriasis Therapies

EP. 5: Therapeutic Potential of TYK2 Inhibition in Psoriasis

EP. 6: Selectivity of TYK2 Inhibition in Psoriasis

EP. 7: Understanding the FDA-Approved TYK2 Inhibitor in Psoriasis

EP. 8: Efficacy and Safety of Zasocitinib in Psoriasis and the Ideal Candidates for TYK2 Inhibitors

EP. 9: Opportunities for TYK2 Inhibition in Moderate Psoriasis

EP. 10: Other Emerging TYK2 Inhibitors in Psoriasis

EP. 11: Therapeutic Potential of TYK2 Inhibition in Psoriatic Arthritis

EP. 12: Shared Decision-Making Strategies with TYK2 Inhibition and Future Direction in Psoriasis Care

Panelists discuss the questions below in this video.
What do we know about the therapeutic potential of TYK2 inhibition in psoriatic arthritis?

Advertisement

Advertisement